Myotonic Dystrophy Type 1 (DM1)
Conditions
Keywords
Myotonic dystrophy type 1, Physical activity, function, balance, mobility
Brief summary
The COVID-19 pandemic exacerbates health problems by reducing access to adapted and advanced physical rehabilitation for several people who need rehabilitation services, including the population with myotonic dystrophy type 1 (DM1). The PACE tool, an innovative web tool integrating pragmatic physical activity programs, seems to be an interesting and innovative intervention to counter physical deficiencies of people with DM1, which are unfortunately accentuated by the pandemic, while reducing the risk of COVID-19 exposure. Objectives: 1) Evaluate the feasibility, usability and acceptability of the PACE tool in the DM1 population; 2) Evaluate the effects of the intervention on their physical and cognitive health; and 3) Estimate the cost-effectiveness ratio of this intervention. Method: Sixty people (experimental group = 40 and control group = 20) will participate in this randomized intervention study. Participants in the experimental group will be assigned to one of the 35 physical activity programs adapted to their condition of the PACE tool. The program must be performed on a daily basis for a period of 12 weeks. Physical and cognitive health will be assessed before and after the remote intervention via ZOOM, for all participants.
Interventions
OTHERRemote activity program
Participant will have to do exercise at home everyday (15min/day)
Sponsors
Université du Québec à Chicoutimi
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Intervention model description
All participants will receive an adapted remote physical program. Half of the participants will do a 12 weeks control prior to intervention.
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* DM1 diagnosis must be confirmed by genetic analysis (juvenile, adults or late-onset phenotypes); * Aged between 18 and 60 years old; * Be able to do exercise; * Subjects must be able to give their consent freely and voluntarily.
Exclusion criteria
* Patients who already train (\>3 times per week or \>150min/week); * Don't speak french or english; * Are not able to do exercise (even in sitting position);
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Functional capacity from baseline to week 12 | Week 12 | Short physical performance battery Functional reach test |
| Change in the Level of physical activity from baseline to week 12 | Week 12 | Rapid Assessment of physical Activity & International Physical Activity Questionnaires |
| Feasability/acceptability of the program and Satisfaction | Week 12 | Number of sessions completed/planned Likert System Usability Scale. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the score of the Fatigue and Daytime Sleepiness Scale from baseline to week 12 | Week 12 | Changes in the score of the Fatigue and Daytime Sleepiness Scale (FDSS). The FDSS is a 12-item questionnaire where all questions are scored from 0 to 2. A higher score means more daytime sleepiness and fatigue. |
| Changes in the Marin apathy scale from baseline to week 12 | Week 12 | Changes in the Marin apathy scale. The Marin apathy scale is scored by the clinician where he interviews the subject and then scores an 18-item list on a scale of 1 to 4. A high score means more apathy. |
Countries
Canada
Outcome results
None listed